Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Immutep Limited | Eftilagimod alpha with pembrolizumab and radiotherapy - (EFTISARC-NEO) | Soft tissue sarcoma | Phase 2 | Data Released | Intravenous | Oncology |
| Immutep Limited | Eftilagimod Alpha with weekly paclitaxel - (AIPAC-003) | Metastatic breast cancer (MBC) | Phase 2/3 | Ongoing | Subcutaneous | Oncology |
| Immutep Limited | Eftilagimod alpha (efti) - (TACTI-004/KEYNOTE-F91) | 1L Non-small cell lung cancer (NSCLC) | Phase 3 | Enrollment Initiation | Subcutaneous | Oncology |
| Impel Pharmaceuticals Inc. | INP105 (Olanzapine) - (CALM 201) | Acute Agitation in Persons with Autism Spectrum Disorder (ASD) | Phase 2a | Intranasal | Psychiatric | |
| Imunon Inc. | IMNN-001 - (OVATION 2) | Ovarian cancer | Phase 3 | Ongoing | Intravenous | Oncology |
| Imunon Inc. | IMNN-001 - (OVATION 3) | Newly diagnosed advanced ovarian cancer | Phase 3 | Ongoing | Intravenous | Oncology |
| IMV Inc. | Maveropepimut-S (DPX-Survivac) and KEYTRUDA (pembrolizumab) - (VITALIZE) | Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2b | Intramuscular and intravenous | Oncology | |
| IMV Inc. | Maveropepimut-S (DPX-Survivac) and epacadostat - (Avalon) | Platinum Resistant Ovarian Cancer | Phase 2b | Intramuscular | Oncology |
